GlassScriptPhysician profile
Heather M Hitesman
NPI 1992259642
$1,895.49
in general payments reported to CMS, 2019-2025
35 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $158 · 2023: $886 · 2024: $389 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568 · Education: $29.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.32 |
| Education | $29.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $391.60 | 2021-2025 | |
| Axsome Therapeutics, INC. | $229.90 | 2023-2025 | Sunosi |
| Novartis Pharmaceuticals Corporation | $164.24 | 2022-2025 | |
| Biogen, INC. | $107.19 | 2023-2024 | Vumerity, Tysabri, Plegridy |
| Neurocrine Biosciences, INC. | $77.73 | 2023-2024 | Ingrezza, Ongentys |
| Pfizer INC. | $76.47 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $68.20 | 2022-2023 | Rytary |
| Inspire Medical Systems, INC. | $67.71 | 2023-2024 | Inspire |
| Neurelis, INC. | $64.17 | 2023-2024 | Valtoco |
| Eisai INC. | $59.90 | 2021-2023 | |
| Lundbeck LLC | $35.90 | 2023 | Vyepti |
| Amgen INC. | $34.12 | 2022-2023 | Aimovig |
| Impel Pharmaceuticals INC. | $33.58 | 2022-2023 | Trudhesa |
| Idorsia Pharmaceuticals US INC | $33.15 | 2022-2023 | Quviviq |
| Mdd US Operations, LLC | $32.47 | 2023 | Apokyn, Myobloc, Xadago |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $28.68 | 2021-2023 | Ocrevus |
| Takeda Pharmaceuticals U.S.A., INC. | $28.34 | 2023 | Gammagard |
| Kyowa Kirin, INC. | $27.67 | 2023 | Nourianz |
| Jazz Pharmaceuticals INC. | $27.47 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $24.22 | 2024 | Wainua |
| Otsuka America Pharmaceutical, INC. | $24.21 | 2023 | Rexulti |
| Argenx US, INC. | $23.94 | 2023 | |
| Almatica Pharma LLC | $23.79 | 2023 | Gralise |
| Sk Life Science, INC. | $21.03 | 2023 | Xcopri |
| Harmony Biosciences LLC | $19.96 | 2024 | |
| Ge Healthcare | $19.95 | 2025 | |
| Tg Therapeutics, INC. | $19.86 | 2024 | |
| Csl Behring | $19.54 | 2023 | Hizentra |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Lilly USA, LLC | $17.09 | 2023 | Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $16.27 | 2021 | |
| Ucb, INC. | $16.03 | 2023 | |
| Abbott Laboratories | $14.80 | 2024 | Infinity |
| Alexion Pharmaceuticals, INC. | $14.44 | 2023 | Ultomiris |
| Sumitomo Pharma America, INC. | $13.97 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Hitesman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.